https://doi.org/10.55788/618bdb63
The PREdiCCT trial aimed to establish to what extent baseline habitual diet, environmental factors, genetic variation, and gut microbiota are associated with the occurrence of flare in patients with Crohnâs disease (CD) or ulcerative colitis (UC).
âWe included participants with CD [n=1,370] or UC [n=1,259] who were in self-reported remission and collected DNA, stool samples, and detailed information about lifestyle and diet,â said Dr Lauranne Derikx (Erasmus MC, the Netherlands) [1]. âWe compared the data of participants who had a disease flare and those who did not have a disease flare.â After 2 years of follow-up, 36% of the participants had experienced a âclinical flare,â which was a self-reported flare, and 13% had had a âhard flareâ, which was defined as an increase in symptoms plus an elevation in CRP and/or calprotectin, as well as a change in IBD therapy. âNo variables were associated with baseline calprotectin,â stressed Dr Derikx.
Severe anxiety was associated with an increased risk for flare in CD (HR 1.86; 95% CI 1.38â2.52; P=0.001) and in UC (HR 1.46; 95% CI 1.08â1.99; P=0.01). Sleep disturbances were linked to an elevated risk of clinical flare in CD (HR 1.58; 95% CI 1.22â2.04; P<0.001) but not in UC. Also, somatisation was related to an increased risk for clinical flare in both CD and UC. âPerhaps even more important, depression and lack of exercise were both associated with a heightened risk for a hard flare in patients with UC,â stated Dr Derikx (see Figure).
Figure: Several psychological factors are associated with clinical and hard flare [1]

In summary, anxiety, sleep disturbances, somatisation, depression, and lack of exercise were all related to an increased risk of flare in patients with IBD. âMore clinical, dietary, genomic, and microbiome data is coming soon from PREdiCCT,â promised Dr Derikx.
- Derikx LAAP, et al. Psychosocial factors are associated with risk of flare in IBD; results from the PREdiCCT study. OP07, 20th Congress of ECCO, 19â22 February 2025, Berlin, Germany.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Kono-S or side-to-side anastomosis for resection in Crohnâs terminal ileitis? Next Article
VEDOKIDS: Long-term outcomes of vedolizumab in paediatric IBD »
« Kono-S or side-to-side anastomosis for resection in Crohnâs terminal ileitis? Next Article
VEDOKIDS: Long-term outcomes of vedolizumab in paediatric IBD »
Table of Contents: ECCO 2025
Featured articles
Novelties and Future Prospects in IBD
Antibody responses predict IBD onset 10 years before diagnosis
Therapeutic antibody clearance reliable predictor for endoscopic outcomes in CD
Higher neoplasia detection rate with virtual chromoendoscopy in real-world IBD study
Reducing the carbon footprint of IBD care
Emerging Treatment Options in IBD
TL1A-LTB axis induces perianal fistulising disease-associated changes in CD
Emulsifier-restrictive diet effective in alleviating symptoms in CD
Could stem cell transplantation be a fruitful solution for refractory CD?
First IL-7 inhibitor for UC shows its potential
Novel TL1A inhibitor achieves high rates at stringent endpoints in UC
Positive results for TL1A inhibitor duvakitug in CD
New Data from Established Agents
Improving efficacy with longer mirikizumab treatment in CD
Long-term upadacitinib data reassuring for patients with UC
EFFICACI: Infliximab or vedolizumab after TNF failure in UC?
Latest data for subcutaneous guselkumab in CD and UC
Long-term use of etrasimod in UC safe and well-tolerated
Sustained efficacy and stable safety profile for risankizumab in UC
VEDOKIDS: Long-term outcomes of vedolizumab in paediatric IBD
More News from ECCO 2025
PREdiCCT: Role of psychosocial factors in IBD flares unravelled
Kono-S or side-to-side anastomosis for resection in Crohnâs terminal ileitis?
Identifying patients at high risk for chronic pouchitis
ECCO consensus on diet and nutrition in IBD
ECCO Topical Review: pouch-related disorders
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
